Deep Track Capital LP Acquires 771,796 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Deep Track Capital LP increased its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 20.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,522,741 shares of the company's stock after buying an additional 771,796 shares during the period. Viridian Therapeutics accounts for approximately 3.2% of Deep Track Capital LP's holdings, making the stock its 9th biggest holding. Deep Track Capital LP owned about 5.71% of Viridian Therapeutics worth $86,701,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in VRDN. Barclays PLC lifted its position in shares of Viridian Therapeutics by 113.1% during the third quarter. Barclays PLC now owns 125,397 shares of the company's stock worth $2,851,000 after purchasing an additional 66,550 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Viridian Therapeutics by 218.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company's stock valued at $9,108,000 after buying an additional 274,641 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in shares of Viridian Therapeutics by 6.8% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 210,899 shares of the company's stock valued at $4,043,000 after buying an additional 13,498 shares during the period. SG Americas Securities LLC increased its stake in shares of Viridian Therapeutics by 89.1% in the 4th quarter. SG Americas Securities LLC now owns 31,085 shares of the company's stock valued at $596,000 after buying an additional 14,644 shares during the period. Finally, Moody Aldrich Partners LLC bought a new stake in shares of Viridian Therapeutics during the fourth quarter worth $1,125,000.

Viridian Therapeutics Stock Down 1.9 %

VRDN traded down $0.24 during trading on Friday, reaching $12.54. The company had a trading volume of 655,726 shares, compared to its average volume of 1,195,808. The business's fifty day moving average price is $13.71 and its 200 day moving average price is $17.53. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $27.20. The company has a market cap of $1.02 billion, a P/E ratio of -2.91 and a beta of 0.57.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. The firm had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business's revenue for the quarter was up .0% on a year-over-year basis. Equities analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. JMP Securities lowered their price objective on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research report on Wednesday. Needham & Company LLC dropped their price target on shares of Viridian Therapeutics from $38.00 to $36.00 and set a "buy" rating for the company in a research note on Wednesday. The Goldman Sachs Group lowered their target price on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a report on Wednesday. HC Wainwright restated a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, April 23rd. Finally, Royal Bank of Canada dropped their price objective on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a report on Wednesday. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $35.18.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.